Innovation
Innovation means more moments like this
We're driven by our deep understanding of the root causes of disease, focusing our R&D in areas like cancer, HIV, and respiratory diseases where we can make the most meaningful difference for people.
Investors
We announced our full year and fourth quarter 2025 results on Wednesday, 4 February.
Press releases
- Blenrep assigned permanent billing code, supporting timely access for patients with relapsed/refractory multiple myeloma
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome

GSK Global links
Visit our Global site for additional features








